Trends in the development of antithrombotic agents.
D000227:Adenine Nucleotides / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D002087:Butyrates / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004041:Dietary Fats; D004176:Dipyridamole / Q000627:therapeutic use; D005032:Ethylestrenol / Q000627:therapeutic use; D005337:Fibrin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D010629:Phenformin / Q000627:therapeutic use; D010653:Phenylbutazone / Q000627:therapeutic use; D010973:Platelet Adhesiveness / Q000187:drug effects; D011205:Povidone / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000517:prevention & control; D011817:Rabbits; D013299:Streptodornase and Streptokinase / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000517:prevention & control; D013927:Thrombosis / Q000517:prevention & control*; D014665:Vasodilator Agents / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D000227:Adenine Nucleotides; D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D000925:Anticoagulants; D002087:Butyrates; D003911:Dextrans; D004041:Dietary Fats; D005343:Fibrinolytic Agents; D006634:Histamine H1 Antagonists; D011453:Prostaglandins; D014665:Vasodilator Agents; D014688:Venoms; D004176:Dipyridamole; D005337:Fibrin; D005032:Ethylestrenol; D010629:Phenformin; D013299:Streptodornase and Streptokinase; D011205:Povidone; D010653:Phenylbutazone; D001241:Aspirin